Introduction
============

As the most common type of adult leukemia, acute myeloid leukemia (AML) is characterized by the excessive expansion of immature myeloblasts from leukemic stem cells (LSCs) ([@b1-or-43-04-1278]). LSC-based gene sets have previously been selected to predict the clinical outcomes of AML, particularly cytogenetically normal AML (CN-AML) ([@b2-or-43-04-1278],[@b3-or-43-04-1278]). The t(8;21) chromosomal rearrangement is one of the most classic genetic abnormalities in AML, and results in a transcript encoding for the fusion protein acute myeloid leukemia 1 protein-protein ETO (AML1-ETO; also known as RUNX1-RUNX1T1) ([@b4-or-43-04-1278]). Following conventional chemotherapy, patients with t(8;21) AML have a relatively favorable prognosis, and steady progress has been observed in the success of t(8;21) AML treatment ([@b5-or-43-04-1278]). However, the relapse and long-term survival rate are less than optimal, and highlight the requirement for more accurate diagnostic and therapeutic strategies ([@b6-or-43-04-1278]); elucidation of the molecular mechanisms of t(8;21) AML are fundamental to the development of more precise diagnostic and therapeutic methods.

Single-cell RNA sequencing (scRNA-seq) has been widely used in developmental biology and oncological research, primarily due to its ability to profile rare or heterogeneous populations of cells ([@b7-or-43-04-1278]). In the present study, scRNA-seq analysis was performed on 87 cells from two patients with t(8;21) AML. Single cells were separated into subpopulations with specific gene marker expression patterns; 31 differentially expressed genes (DEGs) were identified from the cells of patient B, which were considered to be associated with poor patient outcome. Furthermore, three genes, namely AT-rich interaction domain 2 (*ARID2*), lysine methyltransferase 2A (*MLL*) and synaptotagmin binding cytoplasmic RNA interacting protein (*SYNCRIP*) were demonstrated to have prognostic significance in two bulk expression datasets of patients with t(8;21) AML (GSE37642 and GSE6891) ([@b8-or-43-04-1278],[@b9-or-43-04-1278]). To conclude, the present study is, to the best of the authors\' knowledge, the first to demonstrate the single-cell transcriptome profile of two patients with t(8;21) AML, and to suggest several possible prognostic biomarkers.

Materials and methods
=====================

### Patients and specimens

Patient recruitment and sample collection took place at Chinese PLA General Hospital from January 2014 to December 2015. The present study was approved by The Institutional Review Board of Chinese PLA General Hospital, and written informed consent was obtained from both patients with AML. To classify the subtype and prognostic risk of the two patients, chromosome banding, immunophenotyping, flow cytometric analysis and real-time PCR for the fusion genes were conducted.

### Targeted DNA sequencing

Targeted DNA sequencing of bone marrow samples was performed as previously described ([@b10-or-43-04-1278]).

### Single-cell isolation, cDNA amplification and RNA-sequencing

Single cells were isolated from the bone marrow (BM) and peripheral blood (PB) of the two patients. Single-cell loading, capture and cDNA amplification were carried out using the C1™ Single-Cell Auto Prep system (Fluidigm). A total of 87 single cells were loaded into a medium-sized C1 Single-Cell Auto Prep integrated fluidics circuit, as previously described ([@b11-or-43-04-1278]). Afterwards, capture, reverse transcription and cDNA amplification were immediately performed according to the manufacturer\'s instructions ([Fig. S1](#SD1-or-43-04-1278){ref-type="supplementary-material"}). RNA was extracted from samples and cDNA was reverse transcribed (Reverse Transcription System A3500; Promega Corporation) from RNA with TRIzol^®^ reagent (Invitrogen; Thermo Fisher Scientific, Inc.). The reaction conditions used were as follows: Pre-denaturation at 95°C for 15 min; then denaturation at 94°C for 30 sec, annealing at 53°C for 30 sec, and extension at 72°C for 30 sec, 28 cycles; final extension at 72°C for 8 min. Sequencing libraries were constructed using the Nextera XT DNA Sample Prep kit (Illumina, Inc.) and sequenced using the HiSeq2500 platform (Illumina, Inc.). Paired-end 100-bp reads were quality- and adapter-filtered using Trim Galore! software (<http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/>; version 0.4.4).

### Gene fusion prediction

For each cell, the clean reads were mapped to the human genome reference sequences (hg19 version) using the STAR aligner (v2.4.1) ([@b12-or-43-04-1278]), and fusion gene detection was performed using STAR-Fusion (<https://github.com/STAR-Fusion/STAR-Fusion>; v1.3.2), which compared with other methods, was sufficient for fusion RNA prediction ([@b13-or-43-04-1278]).

### Quantitative-PCR (qPCR)

qPCR was performed with the iQ^™^ SYBR^®^ Green Supermix (Bio-Rad Laboratories, Inc.) using cDNA from five cells from patient A (newly diagnosed) with potential AML1-ETO gene fusion. The following reaction conditions were used: Pre-denaturation at 95°C for 1 min; then denaturation at 95°C for 5 sec, and extension at 53°C for 20 sec, 40 cycles; final denaturation at 95°C for 1 min, 60°C for 1 min, 95°C for 30 sec. GAPDH was used as an internal reference gene, and the primer sequences of GAPDH were as follows: Forward, 5′-GAGTCAACGGATTTGGTCGT-3′ and reverse, 5′-TTGATTTTGGAGGGATCTCG-3′; and the primer sequences of AML1-ETO were as follows: Forward, 5′-AACCACTCCACTGCCTTTAACC-3′ and reverse, 5′-TGGAGGAGTCAGCCTAGATTGC-3′. The 2^−∆∆Cq^ method ([@b14-or-43-04-1278]) was used to quantify the AML1-ETO gene fusions. Due to the shortages of cDNA left over after the construction of the sequencing libraries, AML1-ETO fusion in each cell was measured using both the Mx3005P qPCR System (Agilent Technologies, Inc.) and the ABI 7500 Real-Time PCR System (Applied Biosystems; Thermo Fisher Scientific, Inc.).

### Bioinformatics analysis

The high-quality reads were pseudo-aligned with the human genome reference sequence (Ensembl Release 72 of GRCh37) annotations using Kallisto ([@b15-or-43-04-1278]), and quantified as transcript per million (TPM) using AltAnalyze ([@b16-or-43-04-1278]). Expression levels were transformed as log~2~(TPM/10+1) as described in previous studies ([@b17-or-43-04-1278],[@b18-or-43-04-1278]), and single cells were subjected to hierarchical clustering according to their expression levels. Principal component analysis (PCA) was then performed based on the results of hierarchical clustering. Furthermore, unsupervised clustering was performed with scRNA-seq data from patient B using the SC3 pipeline (version 1.12.0) ([@b19-or-43-04-1278]). The functions of DGEs were determined through a literature review ([@b20-or-43-04-1278]--[@b36-or-43-04-1278]). Interactions between DEGs were analyzed using the Gene Multiple Association Network Integration Algorithm (GeneMANIA; <http://www.genemania.org/>; accessed July 24, 2019) ([@b37-or-43-04-1278]). The Search Tool for the Retrieval of Interacting Genes (STRING; <https://string-db.org/>; accessed July 24, 2019) was used to investigate the protein-protein interactions between DEGs ([@b38-or-43-04-1278]).

### Statistical analysis

The heatmap of 31 DEGs were performed using the pheatmap (<https://CRAN.R-project.org/package=pheatmap>; version 1.0.12) R package. The expression levels of the four marker genes were analyzed using the ggpubr (<https://CRAN.R-project.org/package=ggpubr>; version 1.0.12) R package and Kruskal-Wallis test.

### Survival analysis

The expression matrices of two GEO datasets GSE37642 ([@b9-or-43-04-1278]) and GSE6891 ([@b8-or-43-04-1278]) were downloaded from The National Center of Biotechnology Information using the GEOquery (version 2.52.0) R package ([@b39-or-43-04-1278]). In total, 30 and 22 patients with t(8;21) AML from GSE37642 and GSE6891, respectively, were selected for survival analysis. For each gene, the expression value of a selected probe was used to represent the expression level of the gene. A median, tri-sectional quantile or quartile threshold of expression values was used to categorize patients into high- and low-expression groups. The survminer (<https://CRAN.R-project.org/package=survminer>; version 2.52.0) R package and Log-rank test were used for visualizing the Kaplan-Meier estimates of survival curves.

Results
=======

### scRNA-seq for two patients with t(8;21) AML

The two enrolled female patients represented the two stages of AML: Newly diagnosed (patient A) and relapse after hematopoietic stem cell transplantation (HSCT; patient B). The clinical information of these two patients is presented in [Table I](#tI-or-43-04-1278){ref-type="table"}. The French American-British Cooperative Group Criteria ([@b5-or-43-04-1278]), chromosomal karyotype analysis, flow cytometric analysis, reverse transcription and real-time fluorescent qPCR all suggested that both patients possessed the t(8;21) translocation, which classified them as AML type M2. A total of five cells from patient A were predicted to possess the AML1-ETO (RUNX1-RUNX1T1) gene fusion ([Table SI](#SD2-or-43-04-1278){ref-type="supplementary-material"}), which was confirmed by qPCR ([Fig. S2](#SD1-or-43-04-1278){ref-type="supplementary-material"}). These results based on scRNA-seq data demonstrated the existence of the AML1-ETO fusion in patient A. However, due to the low amount of data, none of the cells from patient B were predicted to harbor AML1-ETO fusions. Moreover, none of the known AML-associated somatic mutations were detected by targeted DNA-sequencing.

The treatment outcome for patient A was more favorable, as she achieved complete remission after a course of chemotherapy, and didn\'t relapse until death from another cause \~15 months later. On the contrary, the outcome for patient B was poor, due to relapse after the 15th course of chemotherapy and a second relapse 3 months after HSCT.

Single cells were isolated from the PB and BM of the two patients, and 87 cells qualified for the generation of RNA-seq data. With the exception of one of the cells (with a total read of 19 million), the total reads of the 87 cells ranged from 0.4 to 9 million ([Table SI](#SD2-or-43-04-1278){ref-type="supplementary-material"}), which was sufficient for scRNA-seq analysis ([@b10-or-43-04-1278]). The median reads of the patient B cells were relatively lower than those from patient A ([Fig. S3](#SD1-or-43-04-1278){ref-type="supplementary-material"}), suggesting their abnormal transcriptional programs.

### Separation of leukemia cell subpopulations

scRNA-seq data were pseudo-aligned and quantified as TPM using Kallisto, an alignment-free-based quantification method ([@b13-or-43-04-1278]). TPM values were then log~2~ transformed (after dividing by 10 and adding 1) as in previous studies ([@b17-or-43-04-1278],[@b18-or-43-04-1278]). Hierarchical clustering by ward. D2 linkage distance was used to separate the 87 cells into six groups ([Fig. 1A](#f1-or-43-04-1278){ref-type="fig"}): Cells from patient A were divided into three groups (A_1, A_2 and A_3), and cells from patient B were divided into another three groups (B_1, B_2 and B_3). As presented in [Fig. 1B](#f1-or-43-04-1278){ref-type="fig"}, the six groups were crudely separated by PCA, and the genes contributing to the separation of these subpopulations were examined using SC3 clustering ([@b19-or-43-04-1278]). In total, 2,138 DEGs were detected ([Table SII](#SD3-or-43-04-1278){ref-type="supplementary-material"}) and the top 50 DEGs are presented in [Fig. 1C](#f1-or-43-04-1278){ref-type="fig"}. Among them, immune-associated genes \[major histocompatibility complex, class II, DR α (*HLA-DRA*), major histocompatibility complex, class II, DR β 1, major histocompatibility complex, class I, E and neural cell adhesion molecule 1\] and a DNA methylation-associated gene \[isocitrate dehydrogenase (NADP(+)) 2\] were identified; 35 cells (40.2%) in clusters 2, 3 and 5 exhibited upregulation of these DEGs.

To examine the identity of cells based on the scRNA-seq data, single-cell consensus clustering (SC3) was performed ([@b19-or-43-04-1278]) using raw read counts of the cells from both patients. As presented in [Fig. 2A](#f2-or-43-04-1278){ref-type="fig"}, 36 patient A cells were separated into three groups: The majority of cells in the A_2 group (9 in 13) were in cluster 1, the majority of the cells in the A_1 group (5 in 7) were in cluster 2, while the cells in the A_3 group were not evenly distributed in cluster 3 (n=9), cluster 2 (n=5) or cluster 1 (n=2). As shown in [Fig. 2B](#f2-or-43-04-1278){ref-type="fig"}, 51 cells from patient B were separated into 3 groups: The majority of cells in the B_1 group (11 in 12) were in cluster 3, cluster 2 comprised mainly of cells in the B_2 group, and all cells in the B_3 group were in cluster 1. The cells were previously separated into distinct subpopulations using hierarchical clustering ([Fig. 1A](#f1-or-43-04-1278){ref-type="fig"}), which was highly consistent with the results of PCA ([Fig. 1B](#f1-or-43-04-1278){ref-type="fig"}). The results of SC3 clustering (using read counts) were also concordant with those of hierarchical clustering using log~2~(TPM/10+1).

Additionally, 3 and 31 DEGs with P\<0.01, corrected for multiple testing using the 'holm' method ([@b19-or-43-04-1278]), were identified in cells from patients A and B, respectively. The identified DEGs were upregulated in 11 of the patient A cells (30.6%) and 27 of the patient B cells (52.9%) in cluster 1 ([Fig. 2A and B](#f2-or-43-04-1278){ref-type="fig"}, respectively). The 3 DEGs in the patient A cells were not reported to be associated with AML, whereas the 31 DEGs in the patient B cells were primarily enriched in cancer-related functions from a literature review ([Table I](#tI-or-43-04-1278){ref-type="table"}). There were differences between the cellular composition and transcription patterns of different tissues (including BM and PB), which has been previously described ([@b40-or-43-04-1278]). The major subtypes and proportions of PB mononuclear cells from a healthy donor are \>80% T cells, \~6% NK cells, \~6% B cells and \~7% myeloid cells; while the major subtypes of BM mononuclear cells (BMMCs) from a healthy donor are \>50% T cells, \~20% B cells, \~10% monocytes and \~20% myeloid cells ([@b40-or-43-04-1278]). Specifically, the level of blast cells and immature erythroids in the BMMCs of a healthy donor is \~15%; whereas, in patients with AML this could be 50--80% ([@b40-or-43-04-1278]). The previous study also suggested that cells from BM could predict the status of patients with AML ([@b40-or-43-04-1278]). Therefore, in the present study, only patient B cells from BM were used in the following analyses.

### Marker-based classification of cell subpopulations from patient B

CD34, CD38, mast/stem cell growth factor receptor Kit (KIT or CD117) and HLA-DRA have been used to sort LSCs or hematopoietic stem/progenitor cells in different leukemia samples ([@b41-or-43-04-1278]--[@b44-or-43-04-1278]). Therefore, these four markers were selected to broadly classify the cell sub-populations from patient B. The expression levels of these four markers (Kruskal-Wallis; P=2.4×10^−8^), CD34 (Kruskal-Wallis; P=4.6×10^−5^), KIT (Kruskal-Wallis; P=0.00039), HLA-DRA (Kruskal-Wallis; P=0.00399) and CD38 (Kruskal-Wallis; P=0.00136) were significantly different between the cells of three clusters ([Fig. 3B-F](#f3-or-43-04-1278){ref-type="fig"}). The expression levels of these four genes were low in the cells of cluster 3, suggesting an inactive state ([Fig. 3A and B](#f3-or-43-04-1278){ref-type="fig"}). The expression levels of 31 DEGs in cluster 3 were also low as a result of SC3 clustering ([Fig. 2B](#f2-or-43-04-1278){ref-type="fig"}). Cells in cluster 1 expressed high levels of CD34 ([Fig. 3C](#f3-or-43-04-1278){ref-type="fig"}), KIT ([Fig. 3D](#f3-or-43-04-1278){ref-type="fig"}) and HLA-DRA ([Fig. 3E](#f3-or-43-04-1278){ref-type="fig"}), suggesting that these cells were 'positive blasts' ([@b44-or-43-04-1278]). Significantly lower expression levels of CD34 and KIT were observed in cluster 2 compared with cluster 1 ([Fig. 3C and D](#f3-or-43-04-1278){ref-type="fig"}), suggesting that these were non-leukemic cells. These results not only demonstrate the functional identities of the cell sub-populations, but also confirmed the accuracy of SC3 clustering.

### Functions and interactions of the 31 DEGs

Numerous genes among the 31 DEGs were associated with hematological malignancies ([Table II](#tII-or-43-04-1278){ref-type="table"}). Internal tandem duplication of receptor-type tyrosine-protein kinase FLT3 (*FLT3*) and partial tandem duplication of lysine methyltransferase 2A (*MLL*) are the most common mutations in AML (with frequencies of 30--45% and 5--10%, respectively, in CN-AML), and are associated with poor therapeutic outcomes ([@b20-or-43-04-1278],[@b21-or-43-04-1278]). Specifically, lymphoid-specific helicase and enhancer of polycomb homolog 1 were associated with epigenetic regulation in hematopoiesis ([@b22-or-43-04-1278]), ring finger protein, LIM domain interacting (*RLIM*) was associated with the ubiquitylation of AML1-ETO and protein PML-retinoic acid receptor α ([@b23-or-43-04-1278]), and programmed cell death 4 was associated with related signaling pathway ([@b24-or-43-04-1278]) in myeloid leukemia. *MLL* (*KMT2A*) was associated with fusions and acute leukemia ([@b25-or-43-04-1278]), and La ribonucleoprotein domain family member 4B ([@b26-or-43-04-1278]), jumonji domain containing 1C (*JMJD1C*) ([@b27-or-43-04-1278]) and *SYNCRIP* ([@b28-or-43-04-1278]) were associated with LSC self-renewal. Additionally, *FLT3* ([@b29-or-43-04-1278]), DEAH-box helicase 15 (*DHX15*) ([@b30-or-43-04-1278]) and *JMJD1C* ([@b31-or-43-04-1278]) were with risk or survival in acute leukemia, *FANCD2* was associated with drug resistance in leukemia ([@b32-or-43-04-1278]), *ARID2* was associated with hematopoietic stem cell (HSC) function ([@b33-or-43-04-1278]), CDC28 protein kinase regulatory subunit 1B was associated with multiple myeloma ([@b34-or-43-04-1278]), *EPC1* was associated with the development of T-cell leukemia ([@b35-or-43-04-1278]). Furthermore, the functions or variations of *JMJD1C* ([@b31-or-43-04-1278]), *RLIM* ([@b23-or-43-04-1278]) and *DHX15* ([@b36-or-43-04-1278]) were associated with t(8;21) AML.

The interactions between these 31 DEGs were also examined ([Fig. 4](#f4-or-43-04-1278){ref-type="fig"}). The results of both gene-gene and protein-protein interaction analyses suggested that the DEGs are functionally related.

### Possible biomarkers for rapid prediction of prognostic risk in t(8;21) AML

Potential prognostic biomarkers from the 31 DEGs of the patient B cells were investigated, which included the DEGs between 'positive blasts' and other cells. The dataset GSE6891 ([@b8-or-43-04-1278]), containing both the overall survival (OS) and event-free survival information of 22 patients with t(8;21) AML, and the dataset GSE37642 ([@b9-or-43-04-1278]) with the OS information of 30 patients with t(8;21) AML, were selected to determine the prognostic significance of the identified DEGs. The expression values of *ARID2, MLL* and *SYNCRIP* could predict the OS outcomes of patients with t(8;21) AML in both datasets with P≤0.052 ([Fig. 5](#f5-or-43-04-1278){ref-type="fig"}). High expression levels of *ARID2* and *MLL* indicate a poor outcome, whilst high expression of *SYNCRIP* suggests a more favorable outcome ([Fig. 5](#f5-or-43-04-1278){ref-type="fig"}). The expression values of various genes in either dataset GSE37642 ([Fig. S4](#SD1-or-43-04-1278){ref-type="supplementary-material"}) or GSE6891 ([Fig. S5](#SD1-or-43-04-1278){ref-type="supplementary-material"}) could also predict the OS outcomes of t(8;21) AML. In summary, the present results from the two bulk expression datasets supported the conclusions from the scRNA-seq data.

Discussion
==========

scRNA-seq of AML undergoing allogeneic HSCT has been previously conducted ([@b40-or-43-04-1278]); however, to the best of the authors\' knowledge, investigations into the malignant development of t(8;21) AML are limited. In the present pilot study, the single-cell transcriptomes of two patients with t(8;21) AML were profiled, and the cells were separated into sub-populations with different gene expression patterns.

Among the 31 identified DEGs in cells from patient B (the treatment outcome for whom was poor), several genes were identified to be associated with leukemia; the prognostic significance of three of these genes, *ARID2, MLL* and *SYNCRIP*, was validated in two t(8;21) AML datasets. *ARID2* is a tumor repressor that plays important roles in the maintenance of HSC homeostasis, and *ARID2* deficiency accelerates the progression of MLL-protein AF-9-induced leukemia ([@b33-or-43-04-1278]). Chromosomal rearrangements of *MLL* are associated with acute leukemia, and subsequently result in poor patient outcome ([@b25-or-43-04-1278]). Together with musashi RNA binding protein 2 indirectly, *SYNCRIP* regulates the myeloid LSC program, and is required for the survival of leukemia cells ([@b28-or-43-04-1278]). The prognostic significance of *ARID2* and *MLL* determined in the present study are consistent with those presented in the literature ([@b25-or-43-04-1278],[@b33-or-43-04-1278]), while that of *SYNCRIP* was the opposite, which may due to the tissue difference and requires further validation in the future. Furthermore, the functional and prognostic significance of the other various genes require future experimental clarification.

scRNA-seq is a powerful technology that is frequently used in cancer research, and the flow cytometric targeting of cell surface antigens has been used to isolate tumor cells in a number of previous studies ([@b17-or-43-04-1278],[@b45-or-43-04-1278]). In the present study, the presence of 'positive blasts' was predicted using marker genes as indicated in a previous study ([@b44-or-43-04-1278]). Different gene-based stemness scores have been developed to determine the risk of AML. The weighted sum of a subset of LSC-related genes has been used to determine the prognosis for AML in a number of previous studies, and a sufficient number of datasets and samples were used for training and validation. However, the LSC-related scores only perform well in CN-AML ([@b2-or-43-04-1278],[@b3-or-43-04-1278]). In the present study, three prognostic biomarkers were identified in AML with an abnormal chromosomal karyotype. This differs from previous studies ([@b2-or-43-04-1278],[@b3-or-43-04-1278]); the candidate genes were analyzed from the high-throughput sequencing data of single cells, rather than selected from microarray expression data of bulk cells, and the biomarkers in the present study are applicable to AML with a t(8;21) translocation.

There are some limitations to the present pilot study. Besides second relapse, the BM samples at other time points, such as new diagnosis, first relapse and after HSCT, were not collected from patient B and the patient has subsequently died. Therefore, it was not possible to track the clonal evolution of t(8;21) AML by taking advantage of scRNA-seq in the present study. A larger number of patients at different disease progression stages, and a larger number of collected cells may better illustrate the clonal evolution and development of t(8;21) AML. Additionally, due to the availability of resources, the dataset used for biomarker validation was not very large. Specific genomic variations, such as single nucleotide variants ([@b40-or-43-04-1278]) and copy number variants ([@b17-or-43-04-1278]), may be inferred in the assistance of genomic sequencing methods in future work. The present study provided evidence that scRNA-seq plays an important role in the study of t(8;21) AML and suggested that strategies promoting scRNA-seq may be valuable techniques for hematological malignancy therapy.
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###### 

Subpopulations of 87 acute myeloid leukemia single cells. (A) Hierarchical clustering separated single cells into six groups. (B) A total of six groups were separated with each other in PCA. (C) SC3 clustering of 87 single cells demonstrated the gene expression features of six groups. PCA, principal component analysis.
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![Distributions of acute myeloid leukemia cell subpopulations in each patient. (A) SC3 clustering of 36 single cells from patient A demonstrated the gene expression features of three groups. (B) SC3 clustering of 51 single cells from patient B demonstrated the gene expression features of three groups.](OR-43-04-1278-g02){#f2-or-43-04-1278}

![Expression patterns of four markers in cell subpopulations from patient B. (A and B) Whole expression patterns of four markers in three cell subpopulations. Expression patterns of (C) CD34, (D) KIT (CD117), (E) HLA-DRA and (F) CD38 in three cell subpopulations. Expression values are presented in log~2~(TPM/10+1) scale, that is, TPM was log-transformed after dividing by 10 and adding 1. KIT, mast/stem cell growth factor receptor Kit; HLA-DRA, major histocompatibility complex, class II, DR α; TPM, transcript per million.](OR-43-04-1278-g03){#f3-or-43-04-1278}

###### 

Gene-gene and protein-protein interaction networks of 31 differentially expressed genes. (A) Co-expression network and (B) genetic network from Gene Multiple Association Network Integration Algorithm. Nodes indicate genes and lines indicate interactions. Gene-gene and protein-protein interaction networks of 31 differentially expressed genes. (C) Protein-protein interaction networks. Nodes indicate proteins and lines indicate interactions.
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![Kaplan-Meier survival curves of t(8;21) patients with acute myeloid leukemia from datasets GSE37642 (n=30) and GSE6891 (n=22) using genes *ARID2, MLL* and *SYNCRIP*. Overall survival curves using *ARID2* for (A) GSE37642 and (B) GSE6891. (C) Event-free survival curve using *ARID2* from the dataset GSE6891. Overall survival curves using *MLL* for (D) GSE37642 and (E) GSE6891. (F) Event-free survival curve using ARID2 from the dataset GSE6891. Overall survival curves using SYNCRIP for (G) GSE37642 and (H) GSE6891. *ARID2*, AT-rich interaction domain 2; *MLL*, lysine methyltransferase 2A; SYNCRIP, synaptotagmin binding cytoplasmic RNA interacting protein.](OR-43-04-1278-g07){#f5-or-43-04-1278}

###### 

Clinical information of two patients with acute myeloid leukemia.

  Name        Age, years   Sex      Tissue   Blast, %^[a](#tfn1-or-43-04-1278){ref-type="table-fn"}^   Stage at analysis    Karyotype
  ----------- ------------ -------- -------- --------------------------------------------------------- -------------------- ---------------
  Patient A   74           Female   PB       81                                                        New diagnosis        46,XX,t(8;21)
  Patient B   29           Female   BM       94                                                        Relapse after HSCT   46,XX,t(8;21)

Percentage blast value was from PB samples of both patients. PB, peripheral blood; BM, bone marrow; HSCT, hematopoietic stem cell transplantation.

###### 

A total of 13 differentially expressed genes were associated with the progression of leukemia.

  Author, year                                   Gene symbol        Full name                                                   Role in leukemia                                                                                                                                                                        (Refs.)
  ---------------------------------------------- ------------------ ----------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------
  Prasad *et al*, 2014                           *HELLS*            Helicase, lymphoid specific                                 Specifically expressed in hematopoietic progenitor cells                                                                                                                                ([@b22-or-43-04-1278])
  Prasad *et al*, 2014; Nakahata *et al*, 2009   *EPC1*             Enhancer of polycomb homolog 1                              Lowly expressed in leukemia cells, involved in chromosomal translocation in ALL                                                                                                         ([@b22-or-43-04-1278],[@b35-or-43-04-1278])
  Kramer *et al*, 2008                           *RLIM*             Ring finger protein, LIM domain interacting                 A substrate of E3-ligase SIAH-1, contributing to the ubiquitin-dependent degradation of AML1-ETO and protein PML-retinoic acid receptor α fusion proteins                               ([@b23-or-43-04-1278])
  Espadinha *et al*, 2017                        *PDCD4*            Programmed cell death 4                                     A tumor suppressor, was repressed by phosphorylated STAT5 and microRNA-21 in chronic myeloid leukemia and AML models                                                                    ([@b24-or-43-04-1278])
  Prasad *et al*, 2014; Meyer *et al*, 2018      *MLL (KMT2A)*      Lysine methyltransferase 2A                                 Highly expressed in the lymphoid lineage, chromosomal rearrangements of MLL are associated with acute leukemias, and display a bad outcome                                              ([@b22-or-43-04-1278],[@b25-or-43-04-1278])
  Zhang *et al*, 2015                            *LARP4B*           La ribonucleoprotein domain family member 4B                Involved in LSC maintenance, and may regulate the cell cycle of LSCs                                                                                                                    ([@b26-or-43-04-1278])
  Zhu *et al*, 2016; Chen *et al*, 2015          *JMJD1C*           Jumonji domain containing 1C                                A coactivator for RUNX1-RUNX1T1, mediates of MLL-AF9- and HOXA9-driven LSC function                                                                                                     ([@b27-or-43-04-1278],[@b31-or-43-04-1278])
  Vu *et al*, 2017                               *SYNCRIP*          Synaptotagmin binding interacting cytoplasmic RNA protein   Interacts with MSI2 indirectly, controls the myeloid LSC program                                                                                                                        ([@b28-or-43-04-1278])
  Thiede *et al*, 2002; Cheng *et al*, 2018      *FLT3*             Fms related tyrosine kinase 3                               Internal tandem duplication of FLT3 results in the failure of leukemia treatment and contribute to a poor prognosis; significantly upregulated in AML and ALL, reduces survival rates   ([@b20-or-43-04-1278],[@b29-or-43-04-1278])
  Pan *et al*, 2017; Christen *et al*, 2019      *DHX15*            DEAH-box helicase 15                                        Regulates cell apoptosis through NF-κB signaling pathway, associated with poor prognosis in AML, with mutations in t(8;21) AML                                                          ([@b30-or-43-04-1278],[@b36-or-43-04-1278])
  Yao *et al*, 2015                              *FANCD2*           FA complementation group D2                                 May confer leukemia resistance to adriamycin via enhanced DNA interstrand crosslink repair                                                                                              ([@b32-or-43-04-1278])
  Liu *et al*, 2018                              *ARID2 (BAF200)*   AT-rich interaction domain 2                                Required for the maintenance of HSC homeostasis, ARID2 deficiency accelerates the progression of MLL-AF9-induced leukemia                                                               ([@b33-or-43-04-1278])
  Walker *et al*, 2019                           *CKS1B*            CDC28 protein kinase regulatory subunit 1B                  Amplification (≥4 copies) of CKS1B was observed in high-risk multiple myeloma                                                                                                           ([@b34-or-43-04-1278])

ALL, acute lymphoid leukemia; AML1-ETO, fusion protein acute myeloid leukemia 1 protein-protein ETO; AML, acute myeloid leukemia; LSC, leukemic stem cell; AF9, protein AF-9; HOXA9, homeobox protein Hox-A9; MSI2, musashi RNA binding protein 2; NF-κB, nuclear factor-κB; HSC, hematopoietic stem cell.
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